HIV/AIDS Clinical Trial
Official title:
Harnessing the Power of Peer Navigation and mHealth to Reduce Health Disparities in Appalachia
NCT number | NCT04378439 |
Other study ID # | IRB00065116 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | April 1, 2022 |
Est. completion date | May 2025 |
By combining two strategies (i.e., peer navigation and mHealth) into a complete, culturally compatible, bilingual intervention to increase the use of needed HIV, STI, and HCV prevention and care services among racially/ethnically diverse GBMSM and transgender women in rural Appalachia. Study Investigators anticipate that participants in the intervention group, relative to counterparts in the delayed-intervention group, will demonstrate increased HIV, STI, and HCV testing.
Status | Recruiting |
Enrollment | 141 |
Est. completion date | May 2025 |
Est. primary completion date | May 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - reside in one of the rural Appalachian catchment countiesreside in one of the rural Appalachian catchment counties - be =18 years of age - report being assigned male sex at birth and having had sex with at least 1 man in past 12 months - provide informed consent |
Country | Name | City | State |
---|---|---|---|
United States | Wake Forest University Health Sciences | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Wake Forest University Health Sciences |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of participants who have Human Immunodeficiency Virus (HIV) testing | baseline | ||
Primary | Number of participants who have Sexually Transmitted Infection (STI) testing | baseline | ||
Primary | Number of participants who have Hepatitis C Virus (HCV) testing | baseline | ||
Primary | Number of participants who have HIV testing | immediate post-intervention (12 months post-baseline) | ||
Primary | Number of participants who have STI testing | immediate post-intervention (12 months post-baseline) | ||
Primary | Number of participants who have HCV testing | immediate post-intervention (12 months post-baseline) | ||
Primary | Number of participants who have HIV testing | 12-month follow-up (24 months post-baseline) | ||
Primary | Number of participants who have STI testing | 12-month follow-up (24 months post-baseline) | ||
Primary | Number of participants who have HCV testing | 12-month follow-up (24 months post-baseline) | ||
Secondary | Number of participants who use prevention--Pre-exposure prophylaxis (PrEP) | baseline, immediate post-intervention (12 months post-baseline), and 12-month follow-up (24 months post-baseline). | ||
Secondary | Number of participants who use prevention--syringe services | baseline, immediate post-intervention (12 months post-baseline), and 12-month follow-up (24 months post-baseline). | ||
Secondary | Number of participants who use HIV care services | Measured through self-report and medical chart abstraction | baseline, immediate post-intervention (12 months post-baseline), and 12-month follow-up (24 months post-baseline). | |
Secondary | Number of participants who use STI treatment services | Measured through self-report and medical chart abstraction | baseline, immediate post-intervention (12 months post-baseline), and 12-month follow-up (24 months post-baseline). | |
Secondary | Number of participants who use HCV treatment services | Measured through self-report and medical chart abstraction | baseline, immediate post-intervention (12 months post-baseline), and 12-month follow-up (24 months post-baseline). | |
Secondary | Number of participants who use gender-affirming care services | Measured through self-report and medical chart abstraction | baseline, immediate post-intervention (12 months post-baseline), and 12-month follow-up (24 months post-baseline). |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03413696 -
Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients
|
||
Completed |
NCT03215901 -
Life Plans Intervention Study
|
N/A | |
Completed |
NCT03289676 -
Storytelling Narrative Communication Intervention for Smoking Cessation in Women Living With HIV
|
Phase 1 | |
Completed |
NCT03268551 -
MEMO-Medical Marijuana and Opioids Study
|
||
Active, not recruiting |
NCT04064567 -
Linking High-Risk Jail Detainees to HIV Pre-Exposure Prophylaxis: PrEP-LINK
|
N/A | |
Completed |
NCT04013295 -
Prize-linked Savings Initiatives for Promoting Better Health and Economic Outcomes in Kenya
|
N/A | |
Recruiting |
NCT04405700 -
Measuring Adverse Pregnancy and Newborn Congenital Outcomes
|
||
Recruiting |
NCT03984136 -
HIV Results Exchange Mechanism on Promoting HIV Testing Among MSM
|
N/A | |
Completed |
NCT02928900 -
Patient Actor Training to Improve HIV Services for Adolescents in Kenya
|
N/A | |
Recruiting |
NCT03268109 -
COGnitive ImpairmenT in Older HIV-infected Patients ≥ 65 Years Old
|
||
Completed |
NCT02797262 -
Measuring and Monitoring Adherence to ART With Pill Ingestible Sensor System
|
N/A | |
Completed |
NCT02376582 -
Safety and Immunogenicity Study of a DNA Vaccine Combined With Protein Vaccine Against HIV/AIDS
|
Phase 1 | |
Completed |
NCT01957865 -
Real-Time Antiretroviral Therapy Adherence Intervention in Uganda
|
N/A | |
Completed |
NCT01616940 -
Minority AIDS Initiative Retention and Re-Engagement Project
|
N/A | |
Terminated |
NCT01443923 -
Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV
|
Phase 4 | |
Completed |
NCT01910714 -
Adapting and Evaluating an EBI to Prevent HIV/AIDS Risk Among Apache Youth
|
N/A | |
Completed |
NCT01084421 -
A Computer-Based Parent/Adolescent HIV Communication Intervention for Latinos
|
N/A | |
Completed |
NCT01596322 -
International HIV Antiretroviral Adherence, Resistance and Survival
|
N/A | |
Completed |
NCT03643705 -
A Nurse-led Intervention to Extend the HIV Treatment Cascade for Cardiovascular Disease Prevention
|
N/A | |
Completed |
NCT03923231 -
Pharmacokinetics of Atazanavir in Special Populations
|